Overview of Dr. Shu
Dr. Catherine Shu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 8 years. She is one of 370 doctors at New York-Presbyterian Hospital and one of 121 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 40 publications and over 500 citings.
Office
177 Fort Washington Ave
# Milstein
New York, NY 10032
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology
Princeton UniversityBSE
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2022 - 2025
NY State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Start of enrollment: 2016 Jun 07
- SGI-110 Plus Durvalumab/Tremelimumab in SCLC Start of enrollment: 2017 Dec 15
- Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Start of enrollment: 2022 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-02-27 - Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases.Somnath Tagore, Lindsay Caprio, Amit Dipak Amin, Kresimir Bestak, Karan Luthria
Nature Medicine. 2025-02-27 - 3 citationsA Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2025-02-01
Press Mentions
Lung Cancer Screening: Do Updated Criteria Address Racial Disparities?January 18th, 2022- Dr. Catherine Shu Discusses a Study with Important Implications in the Treatment of Lung CancerJanuary 17th, 2022
The CDC Launches a “Coronavirus Self-Checker” Bot Called Clara for People in the United StatesMarch 23rd, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
